In #JPM2023 news, a quick round of companies that presented on Monday, but have little overlap with the list of companies I track and the list of fields I post about.
$T Thermo Fisher has 1 slide mentioning NGS, with their Oncomine Dx Express Test and Reporter Dx Software. 
$RXDX Prometheus Biosciences has been working on an #Antibody therapy for #IBD for a while, targeting the T1LA gene.
$VERV Verve Therapeutics working on cardiovascular disease targets. Some in combination with Beam and Vertex.
On Tuesday, $STOK Stoke Therapeutics presented their Non-Mediated Decay RNA therapy, which promotes NMD Exon Exclusion and thus increases the amount of protein available after translation. Single dose >3 month effect.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
